All In Biotech

Drug Trial Radar · NCT01453907

Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers

A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Oct 2011

Primary completion

Jun 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Elusys TherapeuticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will determine the safety and PK of a single IV dose of ETI-204 in subjects 18 to 65 years of age. Three cohorts will be studied with subjects receiving ETI-204. This study will be randomized, double-blind and stratified by gender. Each cohort will contain 36 subjects (including at least four females), 30 who will receive ETI-204 and six who will receive placebo.

Conditions

  • Anthrax

Interventions

  • ETI-204, "Anthim"Drug

    intravenously, single dose

  • placeboDrug

    intravenously, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary ObjectiveTime frame: 71 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quintiles

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.